Janssen Search
Search results
Retinal Disease
Retinal Disease Our Expansive Legacy At Janssen, patient needs set the priorities. We have a legacy of entering spaces with innovations that transform lives. From young children to those young at heart, our commitment to eye diseases is no exception. We ...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
Jun 26, 2023 Belgium This is the first and only single tablet combination therapy to be submitted for review in Europe for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all guideline ...
Our Commitment to Maternal-Fetal Immunology
Welcome to the Johnson & Johnson Maternal-Fetal Newsroom. Below, please find the latest news and information about our ongoing commitment to develop innovative medicines for maternal-fetal immune-mediated diseases. To read more about Johnson & ...
Story – Mental Health Initiatives
Developing Solutions and Creating Access for People With Mental Illness From research to real-world solutions, Janssen has a legacy of developing treatments for mental illnesses. For more than 50 years, our unwavering commitment to mental health has led ...
ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
Apr 03, 2023 United States Addition of 240mg strength allows prescribers flexibility to prescribe one 240mg tablet or four 60mg tablets once-daily based on patient needs HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & ...
Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Feb 09, 2024 United States Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to be under clinical development ...
Cyril Titeux
CYRIL TITEUX COMPANY GROUP CHAIRMAN ASIA PACIFIC JOHNSON & JOHNSON INNOVATIVE MEDICINE Cyril Titeux is Company Group Chairman, Johnson & Johnson Innovative Medicine Asia Pacific, and a member of the Innovative Medicine Group Operating Committee ...
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
May 05, 2024 Updated results reinforce the potential of TAR-210 to transform treatment of non – muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations SAN ANTONIO, May 5, 2024 – Johnson & Johnson announced today ...
TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study
Jan 22, 2024 United States Data illustrates rapid and significant clearance in moderate to severe scalp psoriasis and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission
May 20, 2024 Washington, D.C. (May 20, 2024) – Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative ...